Shirin Hekmatirad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shirin Hekmatirad has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Kiarash Zohori Pour
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Ayatollah Amoli Branch, Islamic Azad University
1 shared publication - Marjan Fallah
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
1 shared publication - Mohammad Abdollahi
Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Nasim Asar
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran
1 shared publication - Saeed Aghebat-Bekheir
Department of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 12 November 2025
- Published by Springer Nature in Molecular & Cellular Toxicology
- Vol. 22 (1) , 1-7
Aluminum phosphide as a model for exploring acute mitochondrial disorders
- 12 November 2025
- Published by Springer Nature in Molecular & Cellular Toxicology
- Vol. 22 (1) , 1-7
Aluminum phosphide as a model for exploring acute mitochondrial disorders
- 2 November 2025
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (6) , 2278-2286
Identification of a novel cisplatin resistance gene in bladder cancer and potential inhibitors
Cisplatin-based regimens are indicated for the treatment of a broad spectrum of solid malignancies. Bladder cancer is among the solid malignancies in which cisplatin is used as the first-line treatment. Despite the high success rate of cisplatin therapy, a subset of patients experience poor prognosis and develop resistance to cisplatin. For this reason, there is still a need to find new drug targets to overcome cisplatin resistance and improve response in patients with bladder cancer. This study aimed to find a potential target to help restore bladder cancer sensitivity to cisplatin. First, two microarray datasets were analyzed to find the gene signatures related to cisplatin resistance. Akinase anchor protein 5 (AKAP5) gene was selected as a possible target in cisplatin resistance. To find a suitable AKAP5 inhibitor, a virtual screening of a FDA-approved library was performed and 5-methyltetrahydrofolate (5-MTHF) was selected for the subsequent investigation. Finally, the effect of AKAP inhibition on the cytotoxicity of cisplatin in 5637 cells was determined using the MTT assay. Molecular docking of the selected inhibitor against AKAP5 was performed to validate the virtual screening results and the docking scores were in line with the virtual screening results. Cotreatment with 5-MTHF significantly increased cytotoxicity in 5637 cells treated with 2.5 μM of cisplatin, compared to the groups not receiving 5-MTHF (P
- 2 November 2025
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (6) , 2278-2286
Identification of a novel cisplatin resistance gene in bladder cancer and potential inhibitors
Cisplatin-based regimens are indicated for the treatment of a broad spectrum of solid malignancies. Bladder cancer is among the solid malignancies in which cisplatin is used as the first-line treatment. Despite the high success rate of cisplatin therapy, a subset of patients experience poor prognosis and develop resistance to cisplatin. For this reason, there is still a need to find new drug targets to overcome cisplatin resistance and improve response in patients with bladder cancer. This study aimed to find a potential target to help restore bladder cancer sensitivity to cisplatin. First, two microarray datasets were analyzed to find the gene signatures related to cisplatin resistance. Akinase anchor protein 5 (AKAP5) gene was selected as a possible target in cisplatin resistance. To find a suitable AKAP5 inhibitor, a virtual screening of a FDA-approved library was performed and 5-methyltetrahydrofolate (5-MTHF) was selected for the subsequent investigation. Finally, the effect of AKAP inhibition on the cytotoxicity of cisplatin in 5637 cells was determined using the MTT assay. Molecular docking of the selected inhibitor against AKAP5 was performed to validate the virtual screening results and the docking scores were in line with the virtual screening results. Cotreatment with 5-MTHF significantly increased cytotoxicity in 5637 cells treated with 2.5 μM of cisplatin, compared to the groups not receiving 5-MTHF (P